EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia

Leukemia. 2007 Oct;21(10):2208-10. doi: 10.1038/sj.leu.2404758. Epub 2007 May 31.

Authors

T Leguay, C Foucaud, M Parrens, O Fitoussi, K Bouabdallah, M A Belaud-Rotureau, R Tabrizi, G Marit, A Pigneux, N Milpied

PMID: 17541400
DOI: 10.1038/sj.leu.2404758

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / adverse effects
Benzamides
Cell Proliferation
Female
Herpesvirus 4, Human / metabolism*
Humans
Imatinib Mesylate
In Situ Hybridization, Fluorescence
Kidney Medulla / virology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Liver / virology*
Lymphoproliferative Disorders / chemically induced
Lymphoproliferative Disorders / metabolism
Lymphoproliferative Disorders / virology*
Middle Aged
Piperazines / adverse effects*
Pyrimidines / adverse effects*
Recurrence
Spleen / virology*
Translocation, Genetic

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate